A trial investigating the feasibility and impact of a novel approach for increasing regular exercise among Hispanic people with Parkinson’s disease — the ethnic group in the U.S. with the highest incidence of the neurodegenerative condition — is now recruiting participants. The aim of the new approach is boosting…
ABBV-951 (foslevodopa/foscarbidopa) — Abbvie’s continuous infusion formulation of levodopa/carbidopa that’s administered under the skin — will now be accessible at low or no cost to people in England with advanced Parkinson’s disease whose severe motor fluctuations are no longer controlled by standard treatments. That’s according to the…
The Yale School of Medicine has announced it will launch the Stephen and Denise Adams Center for Parkinson’s Disease Research, a new center dedicated to changing the way Parkinson’s disease is diagnosed and treated. It will be led by Clemens Scherzer, MD, currently the director of the APDA Center…
Asha Therapeutics has been selected as a Blue Knight company, joining a public-private initiative that focuses on speeding new technology and science to help quickly and effectively deal with emerging dangers to public health and safety. The biopharmaceutical company’s selection was prompted by its proprietary therapeutic design platform, known…
A new blood test that assesses damage on a particular type of DNA may help in the early diagnosis of Parkinson’s disease, before symptoms start, a new study reports. “Currently, Parkinson’s disease is diagnosed largely based on clinical symptoms after significant neurological damage has already occurred,” Laurie Sanders,…
NE3107, BioVie’s experimental oral therapy for Parkinson’s disease, is showing promise as a first-line therapy to ease motor symptoms and as a possible strategy to enhance the benefits of standard carbidopa and levodopa therapy. According to data from a Phase 2 clinical trial and a preclinical study with…
Aspen Neuroscience will use Rune Labs’ digital health platform to remotely collect data from Parkinson’s disease patients currently enrolled in a screening study. The goal of the Trial-Ready Cohort Screening study is to provide a comprehensive view of the disease ahead of patient recruitment for Aspen’s…
The Speech Accessibility Project continues to seek participants for its initiative, which focuses on enhancing voice recognition software for people facing speech difficulties like those associated with Parkinson’s disease. The project gathers voice recordings from people with Parkinson’s and related neurological conditions, such as multiple system atrophy…
Ventus Therapeutics has dosed the first participant in its Phase 1 trial testing VENT-02, a novel oral therapy that features an inhibitor that reaches the brain and targets NLRP3 — a protein that’s linked to brain inflammation in Parkinson’s disease. The trial aims to assess the safety and…
Medications commonly used in the treatment of Parkinson’s disease may affect the body’s ability to control its core temperature, part of the body’s so-called automatic functions, which include sweating, a review study found. Such agents — which include anticholinergic medications and cholinesterase inhibitors, dopamine replacement therapies, and dopamine…
Get regular updates to your inbox.